Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 7.25% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTCamp4 Therapeutics Corp's latest supported as-filed period reports revenue of $1.8M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 7.25% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -713.10% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 18.84% · CORE
Level · gp.fundamentals.operating_margin
Raw value -752.11% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 608.04% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 108.54% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 18.8%; Operating margin moved 11817 bp higher; Operating income decreased 2.7%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 18.8%; Operating margin moved 11817 bp higher; Operating income decreased 2.7%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Shares outstanding increased 211.3%; SBC / revenue moved 4161 bp higher.
2 evidence-backed componentsFree-cash-flow proxy changed -23.9% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
CAMP · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-060234SEC ↗4Aug 31, 2026Period Aug 27, 20260001598549-26-000011SEC ↗4Aug 26, 2026Period Aug 24, 20260001598549-26-000009SEC ↗4Aug 21, 2026Period Aug 19, 20260001598549-26-000007SEC ↗4Aug 19, 2026Period Aug 19, 20260001628280-26-058107SEC ↗10-QAug 13, 2026Period Jun 30, 20260001628280-26-056760SEC ↗8-KAug 13, 2026Period Aug 13, 20260001628280-26-056758SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 31, 2026Filed Sep 2, 2026 | Gold KellyChief Financial Officer | Open Market PurchaseIndirect | 10,000 | $4 | $39,600 | Form 4 ↗ |
| Aug 27, 2026Filed Aug 31, 2026 | Schwab Andrew J.Director | Open Market SaleIndirect | 400,000 | $4 | $1.6M | Form 4 ↗ |
| Aug 24, 2026Filed Aug 26, 2026 | Schwab Andrew J.Director | Open Market SaleIndirect | 10 | $5 | $45 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 21, 2026 | Schwab Andrew J.Director | Open Market SaleIndirect | 32,018 | $5 | $144,081 | Form 4 ↗ |
| Aug 20, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating margin changed +11817 basis points from the comparable as-filed period.
Operating cash flow changed -22.7% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Cash & equivalents changed +121.2% from the comparable as-filed period.
Capex / revenue changed +725 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Current assets changed +119.1% from the comparable as-filed period.
Current liabilities changed +161.0% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001231919-26-000829| Schwab Andrew J.Director |
| Open Market SaleIndirect |
| 114,700 |
| $5 |
| $520,738 |
| Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 | Schwab Andrew J.Director | Open Market SaleIndirect | 45,147 | $5 | $214,900 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 19, 2026 | Tardiff DanielChief Scientific Officer | Open Market SaleDirect | 1,738 | $5 | $8,273 | Form 4 ↗ |
| Aug 3, 2026Filed Aug 5, 2026 | Young Richard ADirector | Open Market PurchaseDirect | 16,378 | $2 | $27,024 | Form 4 ↗ |
| Aug 3, 2026Filed Aug 5, 2026 | Maricich YuriChief Medical Officer | Open Market PurchaseDirect | 6,551 | $2 | $10,809 | Form 4 ↗ |
| Aug 3, 2026Filed Aug 5, 2026 | Gold KellyChief Financial Officer | Open Market PurchaseDirect | 6,551 | $2 | $10,809 | Form 4 ↗ |
| Aug 3, 2026Filed Aug 5, 2026 | Mandel-Brehm JoshChief Executive Officer | Open Market PurchaseDirect | 6,551 | $2 | $10,809 | Form 4 ↗ |
| Aug 3, 2026Filed Aug 5, 2026 | Schwab Andrew J.Director | Grant Or AwardIndirect | 3,179,558 | $2 | $4.9M | Form 4 ↗ |
| Aug 3, 2026Filed Aug 5, 2026 | 5AM Partners VI, LLCReporting owner | Open Market PurchaseIndirect | 3,179,558 | $2 | $4.9M | Form 4 ↗ |
| Jun 10, 2026Filed Jun 12, 2026 | Schwab Andrew J.Director | Grant Or AwardDirect | 28,000 | $0 | $0 | Form 4 ↗ |
| Jun 10, 2026Filed Jun 12, 2026 | WILLIAMS DOUGLAS EDirector | Grant Or AwardDirect | 28,000 | $0 | $0 | Form 4 ↗ |
| Jun 10, 2026Filed Jun 12, 2026 | Young Richard ADirector | Grant Or AwardDirect | 28,000 | $0 | $0 | Form 4 ↗ |